EMAIL THIS PAGE TO A FRIEND

International journal of oncology

Valproic acid inhibits proliferation of HER2-expressing breast cancer cells by inducing cell cycle arrest and apoptosis through Hsp70 acetylation.


PMID 26497673

Abstract

Breast cancer encompasses a heterogeneous group of diseases at the molecular level. It is known that chemosensitivity of breast cancer depends on its molecular subtype. We investigated the growth inhibitory effect of valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, and the mechanism of this inhibition on four breast cancer cell lines with different molecular subtypes. The growth inhibitory effect of VPA in the four different breast cancer cell lines was investigated. The alteration of levels of p21 WAF1, cleaved caspase-3, acetylated Heat shock protein (Hsp) 90, acetylated Hsp70, and acetylated α-tubulin by VPA was examined in VPA-sensitive, human epidermal receptor 2 (HER2)-overexpressing SKBR3 cells. The cell growth inhibition of breast cancer cell lines was dependent on the dose and exposure time of VPA. The cell growth of HER2-overexpressing SKBR3 cell line was inhibited by VPA to a much greater degree than other cell lines studied. In SKBR3 cell line, VPA upregulated expression of p21 WAF1 and cleaved caspase-3 in the early phase. VPA markedly increased Hsp70 acetylation in a time-dependent manner but did not increase Hsp90 acetylation. Our data demonstrated that VPA inhibited cell proliferation and induced cell cycle arrest and apoptosis of HER2-overexpressing breast cancer cells. This anti-proliferation effect might be the direct function of VPA as an HDAC inhibitor. We propose an alternative mechanism whereby acetylation of Hsp70 disrupts the function of Hsp90 and leads to downregulation of its client proteins, including HER2 that might be the indirect function of VPA, in the sense that non-histone proteins are acetylated.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

SAB4501461
Anti-HSP90A, C-Terminal antibody produced in rabbit, affinity isolated antibody
SAB2101093
Anti-HSP90AA1 (ab2) antibody produced in rabbit, affinity isolated antibody
SAB2900334
Anti-HSP90AA1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2107614
Anti-HSP90AA1 antibody produced in rabbit, affinity isolated antibody
SAB2107615
Anti-HSP90AA1 antibody produced in rabbit, affinity isolated antibody
SAB4300541
Anti-HSP90AB1 (Ab-254) antibody produced in rabbit, affinity isolated antibody
SAB2701832
Anti-hsp90ab1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
SAB2701806
Anti-hsp90ab1 antibody produced in rabbit, affinity isolated antibody, buffered aqueous solution
AV09016
Anti-HSP90AB1 antibody produced in rabbit, IgG fraction of antiserum
SAB2107344
Anti-HSP90AB1 antibody produced in rabbit, affinity isolated antibody
SAB4501462
Anti-HSP90B antibody produced in rabbit, affinity isolated antibody
SAB4501463
Anti-HSP90B antibody produced in rabbit, affinity isolated antibody
AV09018 Anti-HSPCB antibody produced in rabbit, IgG fraction of antiserum
SAB1305467
ANTI-HSPCB(N-TERMINAL) antibody produced in rabbit, purified immunoglobulin, buffered aqueous solution
SAB5300449
Monoclonal Anti-HSP90AA1 antibody produced in mouse, clone 5G5, purified immunoglobulin, buffered aqueous solution
SAB5300085 Monoclonal Anti-HSP90AB1 antibody produced in mouse, clone 5G4, ascites fluid
SAB5300086 Monoclonal Anti-HSP90AB1 antibody produced in mouse, clone 1D9, ascites fluid